A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

← catalyst calendar

NCT07469891 · readout ≤ 620 d

Sponsored by Prelude Therapeutics (industry) · PRLD — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

100estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-04-29

actual

When the study began enrolling

Primary completion

Apr 2028

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Apr 2028

estimated

The whole study's end, after follow-up

First posted

2026-03-13

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-31

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Polycythemia Vera (PV)
Myelofibrosis (MF)
Myeloproliferative Neoplasms (MPNs)
Post-Polycythemia Vera Myelofibrosis
Post-Essential Thrombocythemia Myelofibrosis
Primary Myelofibrosis (PMF)

Intervention

Drug: PRT12396

Primary outcomes

what the primary-completion date above is the date OF

Dose limiting toxicity (DLT) of PRT12396

measured Through cycle 1 (4 weeks)

Incidence and severity of Adverse events

measured Through study completion, an average of 2 years

Adverse Events Leading to Dose Modifications or Discontinuation

measured Through study completion, an average of 2 years

Maximum tolerated dose (MTD) and Recommended Dose(s) for Expansion (RDE[s]) of PRT12396

measured Through study completion, an average of 2 years

Permalink · PRLD's whole pipeline · Catalyst calendar · Every registered study · What changed